filmov
tv
Cytomegalovirus ('CMV') Vaccine Candidate

Показать описание
VBI is developing a prophylactic vaccine to prevent cytomegalovirus (“CMV”) infection. CMV is a leading cause of prenatal developmental delays. VBI has completed work for GMP manufacturing of its lead candidate for use in Phase I trials. VBI expects to evaluate safety, tolerability, and also immunological proof of concept in humans during Phase I trials by measuring CMV neutralizing antibodies in fibroblasts and epithelial cells.
Cytomegalovirus ('CMV') Vaccine Candidate
Cytomegalovirus (CMV) vaccine research heralds new approach
Cytomegalovirus Update: For the First Time, a Phase 3 Vaccine Trial | IDWeek 2023
Cytomegalovirus Update: Why Isn’t There a Vaccine? | IDWeek 2023
Studying vaccines for CMV (cytomegalovirus)
Vaccine Against CMV Shows Promise in Clinical Trial
Vaccine Hopes for Cytomegalovirus
Vaccines for the treatment of CMV in stem cell transplant recipients
CMV Awareness Month
CMV Knowledge Vaccine - Dr. Demmler-Harrison
Universal, MHC-E-restricted CD8 T cell responses participate in cytomegalovirus vaccine ...
Cytomegalovirus Update: Congenital CMV Is a ‘Disease of Disparity’ | IDWeek 2023
CMV Knowledge Vaccine - Ashley Haden
Queensland researchers develop experimental vaccine against cytomegalovirus | ABC News
CMV Knowledge Vaccine - Tanitra Carter
Developing Options For Congenital CMV
The Potential of Moderna's mRNA Platform for Developing a Vaccine to Fight CMV
CMV Awareness Month
Studying the link between Cytomegalovirus (CMV) and cervical cancer: Joe Boland
Cytomegalovirus (CMV)
Coronavirus vaccine: Moderna CEO discusses vaccine development
CMV-specific immunoglobulins for transplant patients
Cytomegalovirus (CMV/HHV-5) Made Fun to Learn!
New Twists to Tame the Troll of Transplant (CMV)
Комментарии